Efficacy of tigecycline in complicated skin and skin structure infections and complicated intra-abdominal infections

Journal of Chemotherapy

Volumn 17, Issue SUPPL. 1, 2005, Pages 23-29

  Wilcox, Mark H ^a,b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Glycylcycline; Intra abdominal infection; Skin infection; Tigecycline

Indexed keywords

AZTREONAM; CILASTATIN PLUS IMIPENEM; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABSCESS; AGE; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL THERAPY; APPENDICITIS; BACTEREMIA; BACTEROIDES FRAGILIS; CELLULITIS; CHOLECYSTITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIVERTICULITIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DUODENUM PERFORATION; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; EUROPE; GEOGRAPHIC DISTRIBUTION; HUMAN; INDIA; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LAPAROSCOPY; LAPAROTOMY; LENGTH OF STAY; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MULTICENTER STUDY; NORTH AMERICA; OPEN STUDY; PERCUTANEOUS DRAINAGE; PERIPHERAL VASCULAR DISEASE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PSEUDOMONAS AERUGINOSA; RACE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; SEX; SKIN INFECTION; SMALL INTESTINE PERFORATION; SOFT TISSUE INFECTION; SOUTH AMERICA; STAPHYLOCOCCUS AUREUS; STATISTICAL ANALYSIS; STOMACH PERFORATION; STREPTOCOCCUS PYOGENES; SURGICAL PATIENT; SYSTEMATIC REVIEW;

EID: 28044451949     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2005.17.supplement-1.23     Document Type: Review

References (11)

1. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37(8): 997-1005.
2. Postier R, Klein S, Green S, Loh E. Results of a phase 2, open-label, safety, and efficacy study of tigecycline to treat complicated skin and skin structure infections in hospitalized patients. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. 2003; 43: 416.
3. Graham DR, Talan DA, Nichols RL, et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Infect Dis 2002; 35(4): 381-389.
4. Siami FS, LaFleur BJ, Siami GA. Clinafloxacin versus piperacillin/ tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center. Clin Ther 2002; 24(1): 59-72.
5. Breedt J, Teras J, Gardovskis J, et al. The safety and efficacy of tigecycline in the treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin/aztreonam. Antimicrob Agents Chemother 2005: in press.
6. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005 in press.
7. Mallick R, Solomon S. Risk factors for prolonged hospitalization in treatment of complicated skin infections: evidence from a randomized clinical trial comparing tigecycline with vancomycin/aztreonam. In: American College of Clinical Pharmacy 2005 Spring Forum; 2005 April 10-13, 2005; San Francisco; 2005.
8. Murray J, Wilson S, Klein S, Yellin A, Loh E. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients. A phase 2 clinical trial. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother. 2003; 43: 416.
9. Dartois N, Gioud-Paquet M, Ellis-Grosse EJ, Loh E. Tigecycline vs imipenem/cilastatin for treatment of complicated intra-abdominal infections. In: ICAAC 2004; 2004; October 30-November 2, 2004, Washington DC; 2004.
10. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infect Dis 2005 in press.
11. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E, Tigecycline-200 Study Group. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26(5): 704-714.